IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; hydrochloric acid; sodium hydroxide; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Irinotecan Actavis 100 New Zealand - English - Medsafe (Medicines Safety Authority)

irinotecan actavis 100

teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 100mg; irinotecan hydrochloride trihydrate 100mg - concentrate for injection - 100 mg - active: irinotecan hydrochloride trihydrate 100mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 100mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Irinotecan Actavis 40 New Zealand - English - Medsafe (Medicines Safety Authority)

irinotecan actavis 40

teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 40mg; irinotecan hydrochloride trihydrate 40mg - concentrate for injection - 40 mg - active: irinotecan hydrochloride trihydrate 40mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 40mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Irinotecan Koanaa 20mg/ml, concentrate for solution for infusion (2ml vial) Malta - English - Malta Medicines Authority

irinotecan koanaa 20mg/ml, concentrate for solution for infusion (2ml vial)

koanaa healthcare limited - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 40/2 milligram(s)/millilitre - antineoplastic agents

Irinotecan Koanaa 20mg/ml, concentrate for solution for infusion (5ml vial) Malta - English - Malta Medicines Authority

irinotecan koanaa 20mg/ml, concentrate for solution for infusion (5ml vial)

koanaa healthcare limited - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 100 milligram(s)/5 millilitre - antineoplastic agents

Irinotecan Koanaa 20mg/ml, concentrate for solution for infusion (15ml vial) Malta - English - Malta Medicines Authority

irinotecan koanaa 20mg/ml, concentrate for solution for infusion (15ml vial)

koanaa healthcare limited - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 300/15 milligram(s)/millilitre - antineoplastic agents

Irinotecan Koanaa 20mg/ml Concentrate for Solution for Infusion (25ml vial) Malta - English - Malta Medicines Authority

irinotecan koanaa 20mg/ml concentrate for solution for infusion (25ml vial)

koanaa healthcare limited - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 milligram(s)/millilitre - antineoplastic agents

Irinotecan Mylan 20 mg/ml, concentrate for solution for infusion (2ml Vial) Malta - English - Malta Medicines Authority

irinotecan mylan 20 mg/ml, concentrate for solution for infusion (2ml vial)

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 40/2 mg/ml - antineoplastic agents